rutin and Neoplasms

rutin has been researched along with Neoplasms* in 7 studies

Reviews

1 review(s) available for rutin and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    The oxidative pentose phosphate pathway (PPP) contributes to tumour growth, but the precise contribution of 6-phosphogluconate dehydrogenase (6PGD), the third enzyme in this pathway, to tumorigenesis remains unclear. We found that suppression of 6PGD decreased lipogenesis and RNA biosynthesis and elevated ROS levels in cancer cells, attenuating cell proliferation and tumour growth. 6PGD-mediated production of ribulose-5-phosphate (Ru-5-P) inhibits AMPK activation by disrupting the active LKB1 complex, thereby activating acetyl-CoA carboxylase 1 and lipogenesis. Ru-5-P and NADPH are thought to be precursors in RNA biosynthesis and lipogenesis, respectively; thus, our findings provide an additional link between the oxidative PPP and lipogenesis through Ru-5-P-dependent inhibition of LKB1-AMPK signalling. Moreover, we identified and developed 6PGD inhibitors, physcion and its derivative S3, that effectively inhibited 6PGD, cancer cell proliferation and tumour growth in nude mice xenografts without obvious toxicity, suggesting that 6PGD could be an anticancer target.

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction

2015

Trials

1 trial(s) available for rutin and Neoplasms

ArticleYear
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i.v. infusion of 1500 mg m(-2) monoHER. Five patients were examined by endomyocardial biopsy after reaching a cumulative dose of 300 mg m(-2). Histopathological changes in the cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma possibly by depleting the glutathione defense system in both heart and tumour.

    Topics: Adult; Antibiotics, Antineoplastic; Doxorubicin; Female; Heart Diseases; Humans; Hydroxyethylrutoside; Male; Middle Aged; Myocytes, Cardiac; Neoplasms

2007

Other Studies

5 other study(ies) available for rutin and Neoplasms

ArticleYear
Troxerutin, a natural flavonoid binds to DNA minor groove and enhances cancer cell killing in response to radiation.
    Chemico-biological interactions, 2016, May-05, Volume: 251

    Troxerutin, a flavonoid best known for its radioprotective and antioxidant properties is of considerable interest of study due to its broad pharmacological activities. The present study on troxerutin highlights its abilities to bind DNA and enhance cancer cell killing in response to radiation. Troxerutin showed strong binding with calf thymus DNA in vitro. Troxerutin-DNA interaction was confirmed by CD spectropolarimetry. The mode of binding of troxerutin to DNA was assessed by competing troxerutin with EtBr or DAPI, known DNA intercalator and a minor groove binder, respectively. DAPI fluorescence was drastically reduced with linear increase in troxerutin concentration suggesting possible binding of troxerutin to DNA minor groove. Further, computational studies of docking of troxerutin molecule on mammalian DNA also indicated possible troxerutin-DNA interaction at minor groove of DNA. Troxerutin was found to mainly localize in the nucleus of prostate cancer cells. It induced cytotoxicity in radioresistant (DU145) and sensitive (PC3) prostate cancer cells. When troxerutin pre-treated DU145 and PC3 cells were exposed to γ-radiation, cytotoxicity as estimated by MTT assay, was found to be further enhanced. In addition, the % subG1 population detected by propidium iodide staining also showed similar response when combined with radiation. A similar trend was observed in terms of ROS generation and DNA damage in DU145 cells when troxerutin and radiation were combined. DNA binding at minor groove by troxerutin may have contributed to strand breaks leading to increased radiation induced cell death.

    Topics: Antineoplastic Agents; DNA; DNA Damage; Flavonoids; Humans; Hydroxyethylrutoside; Male; Models, Molecular; Molecular Docking Simulation; Neoplasms; Prostatic Neoplasms; Reactive Oxygen Species

2016
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
    Journal of natural products, 2015, Nov-25, Volume: 78, Issue:11

    AKR1B10 is an NADPH-dependent reductase that plays an important function in several physiological reactions such as the conversion of retinal to retinol, reduction of isoprenyl aldehydes, and biotransformation of procarcinogens and drugs. A growing body of evidence points to the important role of the enzyme in the development of several types of cancer (e.g., breast, hepatocellular), in which it is highly overexpressed. AKR1B10 is regarded as a therapeutic target for the treatment of these diseases, and potent and specific inhibitors may be promising therapeutic agents. Several inhibitors of AKR1B10 have been described, but the area of natural plant products has been investigated sparingly. In the present study almost 40 diverse phenolic compounds and alkaloids were examined for their ability to inhibit the recombinant AKR1B10 enzyme. The most potent inhibitors-apigenin, luteolin, and 7-hydroxyflavone-were further characterized in terms of IC50, selectivity, and mode of action. Molecular docking studies were also conducted, which identified putative binding residues important for the interaction. In addition, cellular studies demonstrated a significant inhibition of the AKR1B10-mediated reduction of daunorubicin in intact cells by these inhibitors without a considerable cytotoxic effect. Although these compounds are moderately potent and selective inhibitors of AKR1B10, they constitute a new structural type of AKR1B10 inhibitor and may serve as a template for the development of better inhibitors.

    Topics: Aldehyde Reductase; Aldo-Keto Reductases; Apigenin; Daunorubicin; Enzyme Inhibitors; Flavones; Flavonoids; HCT116 Cells; Humans; Luteolin; Molecular Conformation; Molecular Structure; Neoplasms

2015
Low molecular weight phosphotyrosine protein phosphatases as emerging targets for the design of novel therapeutic agents.
    Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1

    Topics: Animals; Antineoplastic Agents; Antitubercular Agents; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistance; Isoenzymes; Models, Molecular; Molecular Targeted Therapy; Mycobacterium tuberculosis; Neoplasms; Protein Conformation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins

2012
New Hedgehog/GLI signaling inhibitors from Excoecaria agallocha.
    Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2

    The inhibition of the Hedgehog (Hh) signaling pathway has emerged as an anti-cancer strategy. Three flavonoid glycosides including 2 new compounds (1-2) were isolated from Excoecaria agallocha as Hedgehog/GLI1-mediated transcriptional inhibitors and exhibited cytotoxicity against human pancreatic (PANC1) and prostate (DU145) cancer cells. Our data revealed that compound 1 clearly inhibited the expression of GLI-related proteins (PTCH and BCL-2) and blocked the translocation of GLI1 transcription factors into the nucleus in PANC1. Deleting the Smoothened (Smo) function in PANC1 treated with 1 led to downregulation of the mRNA expression of Ptch. This study describes the first Hh signaling inhibitor which blocks GLI1 movement into the nucleus without interfering with Smo.

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Euphorbiaceae; Flavonoids; Gene Expression Regulation, Neoplastic; Glycosides; Hedgehog Proteins; Humans; Male; Neoplasms; Pancreatic Neoplasms; Patched Receptors; Patched-1 Receptor; Prostatic Neoplasms; Receptors, Cell Surface; Signal Transduction; Transcription Factors; Transcriptional Activation; Zinc Finger Protein GLI1

2011
[Pharmacolymphography with Venalot and Venoruton--a 7 years' report].
    Radiologia diagnostica, 1985, Volume: 26, Issue:1

    Topics: Adult; Coumarins; Drug Combinations; Dysgerminoma; Humans; Hydroxyethylrutoside; Lymphography; Lymphoma; Male; Middle Aged; Neoplasms; Rutin

1985